Spotlight on Pulmonary/Respiratory Medicine

Credits: 1.25 CME / MOC
Reducing Influenza Complications in High-Risk Patients: A Virtual Symposium With Challenging Clinical Cases
Paul G. Auwaerter, MD, MBA, FIDSA
Vindico

Reducing Influenza Complications in High-Risk Patients: A Virtual Symposium With Challenging Clinical Cases

Start

Activity Details

Free CME/MOC
1.25 AMA PRA Category 1 Credit(s)
/ABIM MOC
Released: June 29, 2020
Expires: June 28, 2021
1.25 hours to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Incorporate revised guidelines into practice to improve earlier detection and treatment of patients with influenza and comorbid respiratory conditions.
  • Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
  • Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.

Activity Description

In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.

Faculty

Activity Chair:
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure:
  • Consulting Fee: Advanced Biotherapeutics, DiaSorin
  • Ownership Interest: Johnson & Johnson


Faculty:
Roy F. Chemaly, MD, MPH, FIDSA, FACP
Professor of Medicine
Director, Clinical Virology Research
Director, Infection Control Section
Department of Infectious Diseases/Infection Control, and Employee Health
University of Texas MD Anderson Cancer Center
Houston, TX
  • Disclosure:
  • Consulting Fee: ADMA Biologics, Ansun BioPharma, Chimerix, Genentech, Janssen, Kyorin, Partner Therapeutics, Pulmotect, ReViral, Symbio
  • Speakers Bureau: Merck, Oxford Immunotec, Xenex
  • Contracted Research: Ansun, Chimerix, Gilead, Karius, Merck, Novartis, Oxford Immunotec, Shire/Takeda, Xenex, Viracor
  • Ownership Interest: Xenex


John J. Russell, MD
Clinical Professor of Family and Community Medicine
Thomas Jefferson University
Sidney Kimmel School of Medicine
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA
  • Disclosure:
  • Consulting Fee: GlaxoSmithKline, Sanofi Pasteur
  • Speakers Bureau: Sanofi Pasteur


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Agenda

Introduction
Paul G. Auwaerter, MD, MBA, FIDSA

Influenza Management: What’s New in 2020?
Paul G. Auwaerter, MD, MBA, FIDSA

Challenging Case 1: Diagnosing and Treating Flu in the Nursing Home Patient With COPD
John J. Russell, MD

Challenging Case 2: The Pediatric Asthmatic Patient With Symptoms of Flu
John J. Russell, MD

Challenging Case 3: Managing Flu in an Immunocompromised Patient
Roy F. Chemaly, MD, MPH, FIDSA, FACP

Key Takeaways and Conclusion
Paul G. Auwaerter, MD, MBA, FIDSA

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.

Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447.Telephone: 856-994-9400;Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC
1.25 AMA PRA Category 1 Credit(s)
/ABIM MOC
Released: June 29, 2020
Expires: June 28, 2021
1.25 hours to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Incorporate revised guidelines into practice to improve earlier detection and treatment of patients with influenza and comorbid respiratory conditions.
  • Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
  • Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.

Activity Description

In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.

Faculty

Activity Chair:
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure:
  • Consulting Fee: Advanced Biotherapeutics, DiaSorin
  • Ownership Interest: Johnson & Johnson


Faculty:
Roy F. Chemaly, MD, MPH, FIDSA, FACP
Professor of Medicine
Director, Clinical Virology Research
Director, Infection Control Section
Department of Infectious Diseases/Infection Control, and Employee Health
University of Texas MD Anderson Cancer Center
Houston, TX
  • Disclosure:
  • Consulting Fee: ADMA Biologics, Ansun BioPharma, Chimerix, Genentech, Janssen, Kyorin, Partner Therapeutics, Pulmotect, ReViral, Symbio
  • Speakers Bureau: Merck, Oxford Immunotec, Xenex
  • Contracted Research: Ansun, Chimerix, Gilead, Karius, Merck, Novartis, Oxford Immunotec, Shire/Takeda, Xenex, Viracor
  • Ownership Interest: Xenex


John J. Russell, MD
Clinical Professor of Family and Community Medicine
Thomas Jefferson University
Sidney Kimmel School of Medicine
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA
  • Disclosure:
  • Consulting Fee: GlaxoSmithKline, Sanofi Pasteur
  • Speakers Bureau: Sanofi Pasteur


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Agenda

Introduction
Paul G. Auwaerter, MD, MBA, FIDSA

Influenza Management: What’s New in 2020?
Paul G. Auwaerter, MD, MBA, FIDSA

Challenging Case 1: Diagnosing and Treating Flu in the Nursing Home Patient With COPD
John J. Russell, MD

Challenging Case 2: The Pediatric Asthmatic Patient With Symptoms of Flu
John J. Russell, MD

Challenging Case 3: Managing Flu in an Immunocompromised Patient
Roy F. Chemaly, MD, MPH, FIDSA, FACP

Key Takeaways and Conclusion
Paul G. Auwaerter, MD, MBA, FIDSA

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.

Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447.Telephone: 856-994-9400;Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Pulmonary/Respiratory Medicine Presentations

0.75 CME
Academy for Continued Healthcare Learning
What the PCP Needs to Know About IPF: From Diagnosis to Referral

What the PCP Needs to Know About IPF: From Diagnosis to Referral

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: August 7, 2020
Expires: August 7, 2021
45 minutes to complete

Accredited By

Target Audience

This activity is intended for PCPs and other community-based practitioners who may encounter at-risk patients who should be assessed for IPF and/or referred to specialty ILD care center.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Outline risk factors associated with IPF
  • Interpret findings from the steps in a differential diagnosis of IPF
  • Describe comprehensive care plans for patients with IPF
  • Discuss the role of primary care providers in the diagnosis and management of IPF

Activity Description

In this activity, pulmonologist Gregory Cosgrove, MD, discusses the signs and symptoms of IPF to help PCP learners identify at-risk patients and achieve goals of earlier referral and treatment initiation, ultimately improving patient quality of life. The activity also features an animated whiteboard to illustrate take-home points for the PCP audience.

Statement of Educational Need

Clinicians require education surrounding appropriate identification of IPF patients, implications of guidelines to practice, and the value of referral to a specialist. This activity is designed to provide practical guidance from an expert faculty to help increase awareness of signs and symptoms of IPF, and current and emerging treatment options, in order to optimize patient care across a multidisciplinary team.

Faculty

Gregory P. Cosgrove, MD, FCCP
Associate Professor
National Jewish Health & University of Colorado-Denver
Chief Medical Officer
Pulmonary Fibrosis Foundation
Denver, CO


Conflict of Interest Policy/Disclosure Statement

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.

The following financial relationships have been provided:
Grants/Research Support Recipient: Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Global Blood Therapeutics
Advisor or Review Panel Member: Boehringer Ingelheim, Genentech, Global Blood Therapeutics
Consultant: Boehringer Ingelheim, Genentech, Global Blood Therapeutics 

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None 

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity will take approximately 45 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 80% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Genentech, a member of the Roche Group.

Disclaimer Statement/Disclosure of Unlabeled Use

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Contact Information for Questions About the Activity

For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: August 7, 2020
Expires: August 7, 2021
45 minutes to complete

Accredited By

Target Audience

This activity is intended for PCPs and other community-based practitioners who may encounter at-risk patients who should be assessed for IPF and/or referred to specialty ILD care center.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Outline risk factors associated with IPF
  • Interpret findings from the steps in a differential diagnosis of IPF
  • Describe comprehensive care plans for patients with IPF
  • Discuss the role of primary care providers in the diagnosis and management of IPF

Activity Description

In this activity, pulmonologist Gregory Cosgrove, MD, discusses the signs and symptoms of IPF to help PCP learners identify at-risk patients and achieve goals of earlier referral and treatment initiation, ultimately improving patient quality of life. The activity also features an animated whiteboard to illustrate take-home points for the PCP audience.

Statement of Educational Need

Clinicians require education surrounding appropriate identification of IPF patients, implications of guidelines to practice, and the value of referral to a specialist. This activity is designed to provide practical guidance from an expert faculty to help increase awareness of signs and symptoms of IPF, and current and emerging treatment options, in order to optimize patient care across a multidisciplinary team.

Faculty

Gregory P. Cosgrove, MD, FCCP
Associate Professor
National Jewish Health & University of Colorado-Denver
Chief Medical Officer
Pulmonary Fibrosis Foundation
Denver, CO


Conflict of Interest Policy/Disclosure Statement

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.

The following financial relationships have been provided:
Grants/Research Support Recipient: Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Global Blood Therapeutics
Advisor or Review Panel Member: Boehringer Ingelheim, Genentech, Global Blood Therapeutics
Consultant: Boehringer Ingelheim, Genentech, Global Blood Therapeutics 

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None 

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity will take approximately 45 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 80% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Genentech, a member of the Roche Group.

Disclaimer Statement/Disclosure of Unlabeled Use

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Contact Information for Questions About the Activity

For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org

0.75 CME / MOC
Postgraduate Institute for Medicine
Clinical Transfers℠: State-of-the-Art Management for NSCLC: Novel Targets and Therapies

Clinical Transfers℠: State-of-the-Art Management for NSCLC: Novel Targets and Therapies

Start

Activity Details

Free CME/MOC
0.75 AMA PRA Category 1 Credit(s)™/
ABIM MOC point(s)
Released: July 31, 2020
Expires: July 30, 2021
45 minutes to complete

Accredited By


Target Audience

This activity is designed to meet the educational needs of oncology and pathology clinicians involved in the treatment of patients with non-small cell lung cancer (NSCLC).

Learning Objectives

  • Assess the potential role of novel therapies directed against TROP2 and other emerging targets in the management of non-small cell lung cancer (NSCLC) 
  • Identify the potential impact of HER2-/3-directed therapies on the current NSCLC treatment algorithm

Activity Description

The landscape of precision medicine for non-small cell lung cancer (NSCLC) is continually evolving with an ever-expanding armamentarium of targeted agents. This educational activity is designed to provide a synopsis of novel targets and therapies. Jacob Sands, MD, a thoracic medical oncologist, will provide the latest data for newly approved and investigational MET and RET inhibitors, as well as the latest evidence for drug-antibody conjugates directed towards HER2, HER3, TROP2, and B7-H3.

Statement of Commercial Support

The rapid development of novel targets and therapies for NSCLC exemplifies the precision medicine approach in clinical oncology. The first MET and RET inhibitors have recently joined the ever-expanding treatment armamentarium, and others are currently in development. Data is emerging for antibody-drug conjugates designed to target HER2, HER3, TROP2, and B7-H3. Expert guidance is needed to stay abreast of this continually evolving and increasingly complex therapeutic landscape in order to provide optimal patient care and potentially enroll eligible patients into clinical trials.

Agenda

  1. 1. The importance of broad molecular profiling in NSCLC.
  2. 2. Recently presented data for currently approved and investigational MET and RET inhibitors.
  3. 3. Recently presented data for drug-antibody conjugates targeting HER2, HER3, TROP2, and B7-H3.
  4. 4. Summary

Faculty

Jacob Sands, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA

Jacob Sands, MD received his MD from the University of Cincinnati in 2005. He completed both residency in internal medicine and fellowship training in hematology/oncology at the University of California, Davis. He joined Dana-Farber Cancer Institute in 2017 where he treats patients with lung cancer and leads clinical research, including an NCI-sponsored study evaluating incorporation of checkpoint inhibitor into adjuvant therapy for non-small cell lung cancer. Dr. Sands leads the small cell lung cancer program at Dana-Farber Cancer Institute and sits on the NCCN guidelines committee for small cell lung cancer as well as the guidelines committee for lung screening. Dr. Sands is a member of the IASLC Screening & Early Detection Committee, a scientific advisory board member of the GO2 Foundation for Lung Cancer, a media spokesperson for the American Lung Association, and Treasurer of the Rescue Lung Rescue Life Society.

Conflict of Interest Policy/Disclosure Statement

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.  

Jacob Sands, MD, has affiliations with AstraZeneca, Boehringer Ingelheim, Jazz Pharmaceuticals, Lilly, Medtronic, Pharma Mar (Consulting Fees); Merck (Research).  

Planners and Managers  
The Postgraduate Institute for Medicine planners and managers have nothing to disclose. The RMEI Medical Education, LLC planners and managers have nothing to disclose.  

Accreditation Statement

JAP In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Instructions for Receiving Credit

There is no fee for this educational activity. 

During the period July 31, 2020 through July 30, 2021, participants must:

  1. 1. Read the learning objectives and disclosures
  2. 2. Study the educational activity
  3. 3. Complete the evaluation form

Select the desired certificate and click on Submit. Click on Download Certificate and print the certificate for your records. 

Accreditation Support 
Please contact Postgraduate Institute for Medicine Continuing Medical Education Department at inquiries@pimed.com or by calling 303-799-1930 

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a monthly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Daiichi Sankyo, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Disclosure of Unlabeled Use 
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer 
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.  

Contact Information for Questions about the Activity

Please contact Nicole Neely at nneely@rmei.com for questions regarding this activity.

Activity Details

Free CME/MOC
0.75 AMA PRA Category 1 Credit(s)™/
ABIM MOC point(s)
Released: July 31, 2020
Expires: July 30, 2021
45 minutes to complete

Accredited By


Target Audience

This activity is designed to meet the educational needs of oncology and pathology clinicians involved in the treatment of patients with non-small cell lung cancer (NSCLC).

Learning Objectives

  • Assess the potential role of novel therapies directed against TROP2 and other emerging targets in the management of non-small cell lung cancer (NSCLC) 
  • Identify the potential impact of HER2-/3-directed therapies on the current NSCLC treatment algorithm

Activity Description

The landscape of precision medicine for non-small cell lung cancer (NSCLC) is continually evolving with an ever-expanding armamentarium of targeted agents. This educational activity is designed to provide a synopsis of novel targets and therapies. Jacob Sands, MD, a thoracic medical oncologist, will provide the latest data for newly approved and investigational MET and RET inhibitors, as well as the latest evidence for drug-antibody conjugates directed towards HER2, HER3, TROP2, and B7-H3.

Statement of Commercial Support

The rapid development of novel targets and therapies for NSCLC exemplifies the precision medicine approach in clinical oncology. The first MET and RET inhibitors have recently joined the ever-expanding treatment armamentarium, and others are currently in development. Data is emerging for antibody-drug conjugates designed to target HER2, HER3, TROP2, and B7-H3. Expert guidance is needed to stay abreast of this continually evolving and increasingly complex therapeutic landscape in order to provide optimal patient care and potentially enroll eligible patients into clinical trials.

Agenda

  1. 1. The importance of broad molecular profiling in NSCLC.
  2. 2. Recently presented data for currently approved and investigational MET and RET inhibitors.
  3. 3. Recently presented data for drug-antibody conjugates targeting HER2, HER3, TROP2, and B7-H3.
  4. 4. Summary

Faculty

Jacob Sands, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA

Jacob Sands, MD received his MD from the University of Cincinnati in 2005. He completed both residency in internal medicine and fellowship training in hematology/oncology at the University of California, Davis. He joined Dana-Farber Cancer Institute in 2017 where he treats patients with lung cancer and leads clinical research, including an NCI-sponsored study evaluating incorporation of checkpoint inhibitor into adjuvant therapy for non-small cell lung cancer. Dr. Sands leads the small cell lung cancer program at Dana-Farber Cancer Institute and sits on the NCCN guidelines committee for small cell lung cancer as well as the guidelines committee for lung screening. Dr. Sands is a member of the IASLC Screening & Early Detection Committee, a scientific advisory board member of the GO2 Foundation for Lung Cancer, a media spokesperson for the American Lung Association, and Treasurer of the Rescue Lung Rescue Life Society.

Conflict of Interest Policy/Disclosure Statement

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.  

Jacob Sands, MD, has affiliations with AstraZeneca, Boehringer Ingelheim, Jazz Pharmaceuticals, Lilly, Medtronic, Pharma Mar (Consulting Fees); Merck (Research).  

Planners and Managers  
The Postgraduate Institute for Medicine planners and managers have nothing to disclose. The RMEI Medical Education, LLC planners and managers have nothing to disclose.  

Accreditation Statement

JAP In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Instructions for Receiving Credit

There is no fee for this educational activity. 

During the period July 31, 2020 through July 30, 2021, participants must:

  1. 1. Read the learning objectives and disclosures
  2. 2. Study the educational activity
  3. 3. Complete the evaluation form

Select the desired certificate and click on Submit. Click on Download Certificate and print the certificate for your records. 

Accreditation Support 
Please contact Postgraduate Institute for Medicine Continuing Medical Education Department at inquiries@pimed.com or by calling 303-799-1930 

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a monthly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Daiichi Sankyo, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Disclosure of Unlabeled Use 
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer 
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.  

Contact Information for Questions about the Activity

Please contact Nicole Neely at nneely@rmei.com for questions regarding this activity.

1.00 CME
Vindico
Checkpoint Inhibitors as First-line Treatments for Lung Cancer: What You Need to Know

Checkpoint Inhibitors as First-line Treatments for Lung Cancer: What You Need to Know

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: July 28, 2020
Expires: July 27, 2021
1 hour to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is hematologist-oncologists, oncologists, nurses, physician assistants and other health care professionals involved in the management of patients with lung cancer.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Compare available checkpoint inhibitor-based approaches for the management of patients with advanced non–small cell lung cancer (NSCLC) in order to guide individualization of first-line treatment.
  • Assess the latest clinical evidence regarding the use of immune checkpoint inhibitors for patients with small cell lung cancer (SCLC), including those with extensive disease.

Activity Description

Lung cancer remains the leading cause of cancer death among both men and women. The American Cancer Society estimates that during 2020, there will be approximately 228,820 new cases of lung cancer and about 135,720 deaths from this disease in the United States. More than half of patients die within 1 year of diagnosis, and the 5-year survival for advanced disease is extremely limited. Utilization of recently approved immune-checkpoint inhibitors (ICIs) in treatment regimens for both non–small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) has demonstrated clinical benefit and durable responses in some patients, providing a potential for enhanced long-term survival. In this monograph, faculty discuss the use of checkpoint inhibitors in advanced lung cancer, emphasizing new data on the use of these regimens in the first-line setting of advanced disease. Experts will also review appropriate use of ICIs in monotherapy and combination regimens, highlighting new indications for treating NSCLC and SCLC.

Agenda

  • Checkpoint Inhibitors for First-line Treatment of Advanced Non–Small Cell Lung Cancer – Mark A. Socinski, MD
  • Case Example 1: A Patient With Non–Small Cell Lung Cancer – Mark A. Socinski, MD
  • Checkpoint Inhibitors in Small Cell Lung Cancer – Leora Horn, MD, MSc, FRCPC
  • Case Example 2: A Patient With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer – Leora Horn, MD, MSc, FRCPC

Faculty

Leora Horn, MD, MSc, FRCPC
Ingram Associate Professor of Cancer Research
Director Thoracic Oncology Research Program
Vanderbilt Ingram Cancer Center
Nashville, TN
Disclosures:
Consulting Fee: Amgen, AstraZeneca, Bayer, EMD Serono, Genentech-Roche, Incyte, Merck, Pfizer


Mark A. Socinski, MD
Executive Medical Director
AdventHealth Cancer Institute
Orlando, FL
Disclosures:
Consulting Fee: AstraZeneca, Bayer, Bristol-Myers Squibb, Genentech, Guardant, Merck
Speakers Bureau: AstraZeneca, Bayer, Bristol-Myers Squibb, Genentech, Guardant, Merck
Contracted Research: AstraZeneca, Genentech, Novartis, Spectrum


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Medical Writer:
The articles in this ePublication were composed by medical writer Valerie Zimmerman, PhD, based on the presentations of Drs. Socinski and Horn at a virtual CME-certified web program recorded on May 28, 2020. The monograph has been approved by each of the authors individually as an accurate representation of their presentation.
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

This continuing medical education activity is provided by Vindico Medical Education. Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For the purpose of recertifying with ANCC, AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME can be used.

American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.0 hours credit for completing this program.

This enduring material is approved for 1 year from the date of original release July 28, 2020 to July 27, 2021.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 70% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at cme@vindicoCME.com

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: July 28, 2020
Expires: July 27, 2021
1 hour to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is hematologist-oncologists, oncologists, nurses, physician assistants and other health care professionals involved in the management of patients with lung cancer.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Compare available checkpoint inhibitor-based approaches for the management of patients with advanced non–small cell lung cancer (NSCLC) in order to guide individualization of first-line treatment.
  • Assess the latest clinical evidence regarding the use of immune checkpoint inhibitors for patients with small cell lung cancer (SCLC), including those with extensive disease.

Activity Description

Lung cancer remains the leading cause of cancer death among both men and women. The American Cancer Society estimates that during 2020, there will be approximately 228,820 new cases of lung cancer and about 135,720 deaths from this disease in the United States. More than half of patients die within 1 year of diagnosis, and the 5-year survival for advanced disease is extremely limited. Utilization of recently approved immune-checkpoint inhibitors (ICIs) in treatment regimens for both non–small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) has demonstrated clinical benefit and durable responses in some patients, providing a potential for enhanced long-term survival. In this monograph, faculty discuss the use of checkpoint inhibitors in advanced lung cancer, emphasizing new data on the use of these regimens in the first-line setting of advanced disease. Experts will also review appropriate use of ICIs in monotherapy and combination regimens, highlighting new indications for treating NSCLC and SCLC.

Agenda

  • Checkpoint Inhibitors for First-line Treatment of Advanced Non–Small Cell Lung Cancer – Mark A. Socinski, MD
  • Case Example 1: A Patient With Non–Small Cell Lung Cancer – Mark A. Socinski, MD
  • Checkpoint Inhibitors in Small Cell Lung Cancer – Leora Horn, MD, MSc, FRCPC
  • Case Example 2: A Patient With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer – Leora Horn, MD, MSc, FRCPC

Faculty

Leora Horn, MD, MSc, FRCPC
Ingram Associate Professor of Cancer Research
Director Thoracic Oncology Research Program
Vanderbilt Ingram Cancer Center
Nashville, TN
Disclosures:
Consulting Fee: Amgen, AstraZeneca, Bayer, EMD Serono, Genentech-Roche, Incyte, Merck, Pfizer


Mark A. Socinski, MD
Executive Medical Director
AdventHealth Cancer Institute
Orlando, FL
Disclosures:
Consulting Fee: AstraZeneca, Bayer, Bristol-Myers Squibb, Genentech, Guardant, Merck
Speakers Bureau: AstraZeneca, Bayer, Bristol-Myers Squibb, Genentech, Guardant, Merck
Contracted Research: AstraZeneca, Genentech, Novartis, Spectrum


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Medical Writer:
The articles in this ePublication were composed by medical writer Valerie Zimmerman, PhD, based on the presentations of Drs. Socinski and Horn at a virtual CME-certified web program recorded on May 28, 2020. The monograph has been approved by each of the authors individually as an accurate representation of their presentation.
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

This continuing medical education activity is provided by Vindico Medical Education. Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For the purpose of recertifying with ANCC, AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME can be used.

American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.0 hours credit for completing this program.

This enduring material is approved for 1 year from the date of original release July 28, 2020 to July 27, 2021.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 70% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at cme@vindicoCME.com

0.75 CME
Integrity Continuing Education, Inc.
Advancing Diagnosis and Individualized Treatment of Severe Asthma Through Application of Guidelines and Latest Evidence

Advancing Diagnosis and Individualized Treatment of Severe Asthma Through Application of Guidelines and Latest Evidence

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: July 22, 2020
Expires: July 22, 2021
45 minutes to complete

Accredited By

Target Audience

This educational initiative has been designed for allergists, pulmonologists, fellows, and internal medicine physicians involved in the management of patients with severe asthma.

Learning Objectives

  • Demonstrate the ability to diagnose patients with severe versus difficult-to-treat versus persistent uncontrolled asthma
  • Describe the risks of OCS overuse and summarize strategies to reduce OCS use in severe asthma
  • Employ biomarker testing in the evaluation of severe asthma and utilize results to classify patients with severe asthma
  • Develop personalized treatment plans for patients with severe asthma that are consistent with current evidence-based recommendations

Activity Description

Interactive Puzzle Activity

Statement of Educational Need

Severe asthma remains a disease with a high economic, healthcare, and patient burden. Patients with severe asthma suffer frequent exacerbations and the unpredictability of their disease. Prior to the availability of newer therapies that provide an opportunity to improve the management of patients with severe asthma, many patients relied on oral corticosteroids (OCS) as a mainstay of treatment. In fact, Cataldo et al. reported in 2020 that many patients with severe asthma were self-medicating with OCS during episodes of worsening symptoms or as prevention of such episodes in addition to physician-diagnosed exacerbation management. The utility of new therapies is underscored by the need for clinicians to be competent to make an efficient and accurate diagnosis and classification of severe asthma, to possess knowledge of recently released guidelines for severe asthma management, and to be able to select appropriate individualized therapy based on patient profiles and desires. This program has been designed to ensure that fellows and post-specialty-trained clinicians are able to meet the needs of the diverse population of severe asthma patients and design effective treatment plans to reduce symptoms, exacerbations, and the continued need for OCS in patients with severe asthma. 

Faculty

Reynold A. Panettieri, Jr., MD
Professor of Medicine
Robert Wood Johnson Medical School
Vice Chancellor, Clinical & Translational Science
Director, Rutgers Institute for Translational Medicine & Science
New Brunswick, New Jersey
Emeritus Professor of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Reynold A. Panettieri, Jr., MD​
Consulting Fees: AstraZeneca, MedImmune, RIFM, Equillium, Theravance
Speakers’ Bureaus: AstraZeneca, Sanofi, Genentech
Contracted Research: AstraZeneca, MedImmune, RIFM, Genentech, OncoArendi

Patima Tanapat, PhD, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of July 22, 2020 through July 22, 2021, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or info@integrityce.com.

Statement of Commercial Support

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: July 22, 2020
Expires: July 22, 2021
45 minutes to complete

Accredited By

Target Audience

This educational initiative has been designed for allergists, pulmonologists, fellows, and internal medicine physicians involved in the management of patients with severe asthma.

Learning Objectives

  • Demonstrate the ability to diagnose patients with severe versus difficult-to-treat versus persistent uncontrolled asthma
  • Describe the risks of OCS overuse and summarize strategies to reduce OCS use in severe asthma
  • Employ biomarker testing in the evaluation of severe asthma and utilize results to classify patients with severe asthma
  • Develop personalized treatment plans for patients with severe asthma that are consistent with current evidence-based recommendations

Activity Description

Interactive Puzzle Activity

Statement of Educational Need

Severe asthma remains a disease with a high economic, healthcare, and patient burden. Patients with severe asthma suffer frequent exacerbations and the unpredictability of their disease. Prior to the availability of newer therapies that provide an opportunity to improve the management of patients with severe asthma, many patients relied on oral corticosteroids (OCS) as a mainstay of treatment. In fact, Cataldo et al. reported in 2020 that many patients with severe asthma were self-medicating with OCS during episodes of worsening symptoms or as prevention of such episodes in addition to physician-diagnosed exacerbation management. The utility of new therapies is underscored by the need for clinicians to be competent to make an efficient and accurate diagnosis and classification of severe asthma, to possess knowledge of recently released guidelines for severe asthma management, and to be able to select appropriate individualized therapy based on patient profiles and desires. This program has been designed to ensure that fellows and post-specialty-trained clinicians are able to meet the needs of the diverse population of severe asthma patients and design effective treatment plans to reduce symptoms, exacerbations, and the continued need for OCS in patients with severe asthma. 

Faculty

Reynold A. Panettieri, Jr., MD
Professor of Medicine
Robert Wood Johnson Medical School
Vice Chancellor, Clinical & Translational Science
Director, Rutgers Institute for Translational Medicine & Science
New Brunswick, New Jersey
Emeritus Professor of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Reynold A. Panettieri, Jr., MD​
Consulting Fees: AstraZeneca, MedImmune, RIFM, Equillium, Theravance
Speakers’ Bureaus: AstraZeneca, Sanofi, Genentech
Contracted Research: AstraZeneca, MedImmune, RIFM, Genentech, OncoArendi

Patima Tanapat, PhD, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of July 22, 2020 through July 22, 2021, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or info@integrityce.com.

Statement of Commercial Support

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

0.25 CME / MOC
Vindico
Influenza: Reducing Complications in High-Risk Patients Through Advanced Treatment Options – Curbside Consult: Treating Flu in a 69-year-old Patient With COPD

Influenza: Reducing Complications in High-Risk Patients Through Advanced Treatment Options – Curbside Consult: Treating Flu in a 69-year-old Patient With COPD

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
/ABIM MOC
Released: June 29, 2020
Expires: June 28, 2021
0.25 hours to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Incorporate revised guidelines into practice to improve earlier detection and treatment of patients with influenza and comorbid respiratory conditions.
  • Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
  • Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.

Activity Description

In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.

Faculty

Activity Chair:
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure:
  • Consulting Fee: Advanced Biotherapeutics, DiaSorin
  • Ownership Interest: Johnson & Johnson


Faculty:
John J. Russell, MD
Clinical Professor of Family and Community Medicine
Thomas Jefferson University
Sidney Kimmel School of Medicine
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA
  • Disclosure:
  • Consulting Fee: GlaxoSmithKline, Sanofi Pasteur
  • Speakers Bureau: Sanofi Pasteur


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Agenda

Curbside Consult: Treating Flu in a 69-year-old Patient With COPD
Paul G. Auwaerter, MD, MBA, FIDSA and John J. Russell, MD

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.

Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447.Telephone: 856-994-9400;Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
/ABIM MOC
Released: June 29, 2020
Expires: June 28, 2021
0.25 hours to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Incorporate revised guidelines into practice to improve earlier detection and treatment of patients with influenza and comorbid respiratory conditions.
  • Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
  • Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.

Activity Description

In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.

Faculty

Activity Chair:
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure:
  • Consulting Fee: Advanced Biotherapeutics, DiaSorin
  • Ownership Interest: Johnson & Johnson


Faculty:
John J. Russell, MD
Clinical Professor of Family and Community Medicine
Thomas Jefferson University
Sidney Kimmel School of Medicine
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA
  • Disclosure:
  • Consulting Fee: GlaxoSmithKline, Sanofi Pasteur
  • Speakers Bureau: Sanofi Pasteur


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Agenda

Curbside Consult: Treating Flu in a 69-year-old Patient With COPD
Paul G. Auwaerter, MD, MBA, FIDSA and John J. Russell, MD

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.

Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447.Telephone: 856-994-9400;Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.25 CME / MOC
Vindico
Influenza: Reducing Complications in High-Risk Patients Through Advanced Treatment Options – Curbside Consult: Managing Flu in an Immunocompromised Patient

Influenza: Reducing Complications in High-Risk Patients Through Advanced Treatment Options – Curbside Consult: Managing Flu in an Immunocompromised Patient

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
/ABIM MOC
Released: June 29, 2020
Expires: June 28, 2021
0.25 hours to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
  • Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.

Activity Description

In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.

Faculty

Activity Chair:
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure:
  • Consulting Fee: Advanced Biotherapeutics, DiaSorin
  • Ownership Interest: Johnson & Johnson


Faculty:
Roy F. Chemaly, MD, MPH, FIDSA, FACP
Professor of Medicine
Director, Clinical Virology Research
Director, Infection Control Section
Department of Infectious Diseases/Infection Control, and Employee Health
University of Texas MD Anderson Cancer Center
Houston, TX
  • Disclosure:
  • Consulting Fee: ADMA Biologics, Ansun BioPharma, Chimerix, Genentech, Janssen, Kyorin, Partner Therapeutics, Pulmotect, ReViral, Symbio
  • Speakers Bureau: Merck, Oxford Immunotec, Xenex
  • Contracted Research: Ansun, Chimerix, Gilead, Karius, Merck, Novartis, Oxford Immunotec, Shire/Takeda, Xenex, Viracor
  • Ownership Interest: Xenex


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Agenda

Curbside Consult: Managing Flu in an Immunocompromised Patient
Paul G. Auwaerter, MD, MBA, FIDSA and Roy F. Chemaly, MD, MPH, FIDSA, FACP

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.

Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447.Telephone: 856-994-9400;Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
/ABIM MOC
Released: June 29, 2020
Expires: June 28, 2021
0.25 hours to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
  • Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.

Activity Description

In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.

Faculty

Activity Chair:
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure:
  • Consulting Fee: Advanced Biotherapeutics, DiaSorin
  • Ownership Interest: Johnson & Johnson


Faculty:
Roy F. Chemaly, MD, MPH, FIDSA, FACP
Professor of Medicine
Director, Clinical Virology Research
Director, Infection Control Section
Department of Infectious Diseases/Infection Control, and Employee Health
University of Texas MD Anderson Cancer Center
Houston, TX
  • Disclosure:
  • Consulting Fee: ADMA Biologics, Ansun BioPharma, Chimerix, Genentech, Janssen, Kyorin, Partner Therapeutics, Pulmotect, ReViral, Symbio
  • Speakers Bureau: Merck, Oxford Immunotec, Xenex
  • Contracted Research: Ansun, Chimerix, Gilead, Karius, Merck, Novartis, Oxford Immunotec, Shire/Takeda, Xenex, Viracor
  • Ownership Interest: Xenex


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Agenda

Curbside Consult: Managing Flu in an Immunocompromised Patient
Paul G. Auwaerter, MD, MBA, FIDSA and Roy F. Chemaly, MD, MPH, FIDSA, FACP

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.

Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447.Telephone: 856-994-9400;Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.25 CME / MOC
Vindico
Influenza: Reducing Complications in High-Risk Patients Through Advanced Treatment Options – Curbside Consult: An Adult Patient With Asthma and Symptoms of Flu

Influenza: Reducing Complications in High-Risk Patients Through Advanced Treatment Options – Curbside Consult: An Adult Patient With Asthma and Symptoms of Flu

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
/ABIM MOC
Released: June 29, 2020
Expires: June 28, 2021
0.25 hours to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Incorporate revised guidelines into practice to improve earlier detection and treatment of patients with influenza and comorbid respiratory conditions.
  • Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
  • Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.

Activity Description

In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.

Faculty

Activity Chair:
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure:
  • Consulting Fee: Advanced Biotherapeutics, DiaSorin
  • Ownership Interest: Johnson & Johnson


Faculty:
John J. Russell, MD
Clinical Professor of Family and Community Medicine
Thomas Jefferson University
Sidney Kimmel School of Medicine
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA
  • Disclosure:
  • Consulting Fee: GlaxoSmithKline, Sanofi Pasteur
  • Speakers Bureau: Sanofi Pasteur


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Agenda

Curbside Consult: An Adult Patient With Asthma and Symptoms of Flu
Paul G. Auwaerter, MD, MBA, FIDSA and John J. Russell, MD

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.

Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447.Telephone: 856-994-9400;Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
/ABIM MOC
Released: June 29, 2020
Expires: June 28, 2021
0.25 hours to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Incorporate revised guidelines into practice to improve earlier detection and treatment of patients with influenza and comorbid respiratory conditions.
  • Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
  • Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.

Activity Description

In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.

Faculty

Activity Chair:
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure:
  • Consulting Fee: Advanced Biotherapeutics, DiaSorin
  • Ownership Interest: Johnson & Johnson


Faculty:
John J. Russell, MD
Clinical Professor of Family and Community Medicine
Thomas Jefferson University
Sidney Kimmel School of Medicine
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA
  • Disclosure:
  • Consulting Fee: GlaxoSmithKline, Sanofi Pasteur
  • Speakers Bureau: Sanofi Pasteur


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Agenda

Curbside Consult: An Adult Patient With Asthma and Symptoms of Flu
Paul G. Auwaerter, MD, MBA, FIDSA and John J. Russell, MD

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.

Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447.Telephone: 856-994-9400;Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

1.25 CME / MOC
Vindico
Reducing Influenza Complications in High-Risk Patients: A Virtual Symposium With Challenging Clinical Cases

Reducing Influenza Complications in High-Risk Patients: A Virtual Symposium With Challenging Clinical Cases

Start

Activity Details

Free CME/MOC
1.25 AMA PRA Category 1 Credit(s)
/ABIM MOC
Released: June 29, 2020
Expires: June 28, 2021
1.25 hours to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Incorporate revised guidelines into practice to improve earlier detection and treatment of patients with influenza and comorbid respiratory conditions.
  • Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
  • Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.

Activity Description

In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.

Faculty

Activity Chair:
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure:
  • Consulting Fee: Advanced Biotherapeutics, DiaSorin
  • Ownership Interest: Johnson & Johnson


Faculty:
Roy F. Chemaly, MD, MPH, FIDSA, FACP
Professor of Medicine
Director, Clinical Virology Research
Director, Infection Control Section
Department of Infectious Diseases/Infection Control, and Employee Health
University of Texas MD Anderson Cancer Center
Houston, TX
  • Disclosure:
  • Consulting Fee: ADMA Biologics, Ansun BioPharma, Chimerix, Genentech, Janssen, Kyorin, Partner Therapeutics, Pulmotect, ReViral, Symbio
  • Speakers Bureau: Merck, Oxford Immunotec, Xenex
  • Contracted Research: Ansun, Chimerix, Gilead, Karius, Merck, Novartis, Oxford Immunotec, Shire/Takeda, Xenex, Viracor
  • Ownership Interest: Xenex


John J. Russell, MD
Clinical Professor of Family and Community Medicine
Thomas Jefferson University
Sidney Kimmel School of Medicine
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA
  • Disclosure:
  • Consulting Fee: GlaxoSmithKline, Sanofi Pasteur
  • Speakers Bureau: Sanofi Pasteur


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Agenda

Introduction
Paul G. Auwaerter, MD, MBA, FIDSA

Influenza Management: What’s New in 2020?
Paul G. Auwaerter, MD, MBA, FIDSA

Challenging Case 1: Diagnosing and Treating Flu in the Nursing Home Patient With COPD
John J. Russell, MD

Challenging Case 2: The Pediatric Asthmatic Patient With Symptoms of Flu
John J. Russell, MD

Challenging Case 3: Managing Flu in an Immunocompromised Patient
Roy F. Chemaly, MD, MPH, FIDSA, FACP

Key Takeaways and Conclusion
Paul G. Auwaerter, MD, MBA, FIDSA

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.

Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447.Telephone: 856-994-9400;Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC
1.25 AMA PRA Category 1 Credit(s)
/ABIM MOC
Released: June 29, 2020
Expires: June 28, 2021
1.25 hours to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Incorporate revised guidelines into practice to improve earlier detection and treatment of patients with influenza and comorbid respiratory conditions.
  • Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
  • Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.

Activity Description

In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.

Faculty

Activity Chair:
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure:
  • Consulting Fee: Advanced Biotherapeutics, DiaSorin
  • Ownership Interest: Johnson & Johnson


Faculty:
Roy F. Chemaly, MD, MPH, FIDSA, FACP
Professor of Medicine
Director, Clinical Virology Research
Director, Infection Control Section
Department of Infectious Diseases/Infection Control, and Employee Health
University of Texas MD Anderson Cancer Center
Houston, TX
  • Disclosure:
  • Consulting Fee: ADMA Biologics, Ansun BioPharma, Chimerix, Genentech, Janssen, Kyorin, Partner Therapeutics, Pulmotect, ReViral, Symbio
  • Speakers Bureau: Merck, Oxford Immunotec, Xenex
  • Contracted Research: Ansun, Chimerix, Gilead, Karius, Merck, Novartis, Oxford Immunotec, Shire/Takeda, Xenex, Viracor
  • Ownership Interest: Xenex


John J. Russell, MD
Clinical Professor of Family and Community Medicine
Thomas Jefferson University
Sidney Kimmel School of Medicine
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA
  • Disclosure:
  • Consulting Fee: GlaxoSmithKline, Sanofi Pasteur
  • Speakers Bureau: Sanofi Pasteur


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Agenda

Introduction
Paul G. Auwaerter, MD, MBA, FIDSA

Influenza Management: What’s New in 2020?
Paul G. Auwaerter, MD, MBA, FIDSA

Challenging Case 1: Diagnosing and Treating Flu in the Nursing Home Patient With COPD
John J. Russell, MD

Challenging Case 2: The Pediatric Asthmatic Patient With Symptoms of Flu
John J. Russell, MD

Challenging Case 3: Managing Flu in an Immunocompromised Patient
Roy F. Chemaly, MD, MPH, FIDSA, FACP

Key Takeaways and Conclusion
Paul G. Auwaerter, MD, MBA, FIDSA

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.

Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447.Telephone: 856-994-9400;Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

1.50 CME
Integrity Continuing Education, Inc.
Beyond the Guidelines: Optimizing the Management of SSc-ILD

Beyond the Guidelines: Optimizing the Management of SSc-ILD

Start

Activity Details

Free CME
1.5 AMA PRA Category 1 Credit(s)
Released: June 25, 2020
Expires: June 25, 2021
90 minutes to complete

Accredited By

Target Audience

This educational initiative has been designed for pulmonologists, rheumatologists, and internal medicine physicians involved in the care of patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).

Learning Objectives

  • Implement best practice recommendations for ILD screening and assessment of risk for progressive ILD in patients with SSc
  • Outline a tailored approach to SSc-ILD treatment that is consistent with current clinical trial evidence of new regimens
  • Utilize communication strategies that facilitate accurate symptom reporting, improve disease understanding, and promote treatment adherence among patients with SSc-ILD

Activity Description

ILD is associated with early mortality and is the most frequent cause of death among individuals with SSc. Over the past several years, there has been a dramatic increase in awareness of the risk for SSc-ILD, and the need for early diagnosis and treatment to improve health outcomes. Nevertheless, accomplishment of this goal remains difficult for several reasons, including the significant challenge associated with accurately identifying patients at risk for rapidly progressive disease. While a number of risk factors have been previously identified, there are currently no formal guidelines for evaluation and staging. Outcome improvements have been hindered for years due to the lack of approved therapies for SSc-ILD. Change may now be possible with the recent approval of nintedanib for SSc-ILD, the only FDA-approved medicine that slows the rate of decline in pulmonary function. This advance in treatment coupled with the progress of emerging therapies that have shown promise in their capacity to slow, and potentially halt, the progression of fibrosis in SSc-ILD give new hope to clinicians and patients. With this in mind, this program has been designed to provide clinicians with guidance on the integration of new and emerging agents, in addition to the knowledge and skills required to provide patients with SSc-ILD with early diagnosis and optimal disease management.

Faculty

Kristin Highland, MD
Director, Rheumatic Lung Disease Program
Cleveland Clinic
Cleveland, Ohio


Steven D. Nathan, MD
Medical Director, Lung Transplant Program
Director, Advanced Lung Disease Program
Co-director, Inova Pulmonary Hypertension Program
Inova Fairfax Hospital
Fairfax, Virginia

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Kristin Highland, MD
Consulting Fees: Actelion Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc., United Therapeutics
Speakers’ Bureaus: Actelion Pharmaceuticals, Bayer Healthcare, Boehringer Ingelheim Pharmaceuticals, Inc., Gilead Sciences, United Therapeutics
Contracted Research: Actelion Pharmaceuticals, Bayer Healthcare, Boehringer Ingelheim Pharmaceuticals, Inc., Eiger Pharmaceuticals, Genentech, Gossamer Bio, Reata Pharmaceuticals, United Therapeutics

Steven D. Nathan, MD
Consulting Fees: Boehringer Ingelheim Pharmaceuticals, Inc., Galapagos, Roche-Genentech
Speakers’ Bureaus: Boehringer Ingelheim Pharmaceuticals, Inc., Roche-Genentech

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of June 25, 2020 through June 25, 2021 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

Statement of Commercial Support

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Activity Details

Free CME
1.5 AMA PRA Category 1 Credit(s)
Released: June 25, 2020
Expires: June 25, 2021
90 minutes to complete

Accredited By

Target Audience

This educational initiative has been designed for pulmonologists, rheumatologists, and internal medicine physicians involved in the care of patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).

Learning Objectives

  • Implement best practice recommendations for ILD screening and assessment of risk for progressive ILD in patients with SSc
  • Outline a tailored approach to SSc-ILD treatment that is consistent with current clinical trial evidence of new regimens
  • Utilize communication strategies that facilitate accurate symptom reporting, improve disease understanding, and promote treatment adherence among patients with SSc-ILD

Activity Description

ILD is associated with early mortality and is the most frequent cause of death among individuals with SSc. Over the past several years, there has been a dramatic increase in awareness of the risk for SSc-ILD, and the need for early diagnosis and treatment to improve health outcomes. Nevertheless, accomplishment of this goal remains difficult for several reasons, including the significant challenge associated with accurately identifying patients at risk for rapidly progressive disease. While a number of risk factors have been previously identified, there are currently no formal guidelines for evaluation and staging. Outcome improvements have been hindered for years due to the lack of approved therapies for SSc-ILD. Change may now be possible with the recent approval of nintedanib for SSc-ILD, the only FDA-approved medicine that slows the rate of decline in pulmonary function. This advance in treatment coupled with the progress of emerging therapies that have shown promise in their capacity to slow, and potentially halt, the progression of fibrosis in SSc-ILD give new hope to clinicians and patients. With this in mind, this program has been designed to provide clinicians with guidance on the integration of new and emerging agents, in addition to the knowledge and skills required to provide patients with SSc-ILD with early diagnosis and optimal disease management.

Faculty

Kristin Highland, MD
Director, Rheumatic Lung Disease Program
Cleveland Clinic
Cleveland, Ohio


Steven D. Nathan, MD
Medical Director, Lung Transplant Program
Director, Advanced Lung Disease Program
Co-director, Inova Pulmonary Hypertension Program
Inova Fairfax Hospital
Fairfax, Virginia

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Kristin Highland, MD
Consulting Fees: Actelion Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc., United Therapeutics
Speakers’ Bureaus: Actelion Pharmaceuticals, Bayer Healthcare, Boehringer Ingelheim Pharmaceuticals, Inc., Gilead Sciences, United Therapeutics
Contracted Research: Actelion Pharmaceuticals, Bayer Healthcare, Boehringer Ingelheim Pharmaceuticals, Inc., Eiger Pharmaceuticals, Genentech, Gossamer Bio, Reata Pharmaceuticals, United Therapeutics

Steven D. Nathan, MD
Consulting Fees: Boehringer Ingelheim Pharmaceuticals, Inc., Galapagos, Roche-Genentech
Speakers’ Bureaus: Boehringer Ingelheim Pharmaceuticals, Inc., Roche-Genentech

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of June 25, 2020 through June 25, 2021 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

Statement of Commercial Support

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

1.00 CME / CNE / CPE
Integrity Continuing Education, Inc.
Clearing the Air: Recognizing the Role of Eosinophils and IL-5 Inhibitors in Severe Asthma and Associated Conditions

Clearing the Air: Recognizing the Role of Eosinophils and IL-5 Inhibitors in Severe Asthma and Associated Conditions

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: June 25, 2020
Expires: June 25, 2021
1 hour to complete

Accredited By

This CME activity for ACCME credit is provided by Integrity Continuing Education.
This CE activity for ANCC and ACPE credit is jointly provided by Global Education Group and Integrity Continuing Education.

Target Audience

This educational initiative has been designed for pulmonologists, allergists, fellows, medical residents, nurse practitioners, physician assistants, nurses, and other allied health care professionals who manage patients with asthma and other eosinophilic-associated diseases.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe the role of eosinophilia in severe asthma and EGPA
  • Explain why severe asthma comorbidities and rare orphan diseases have an impact on treatment of severe asthma
  • Differentiate between available biologic therapies and evaluate their impact on lung function, asthma exacerbations, and dependence on oral corticosteroids

Activity Description

This program was designed to increase the clinician’s understanding of severe eosinophilic diseases that target the lungs and enable them to differentiate between available treatments to facilitate improved symptoms, lighter disease burden, fewer exacerbations, and reduced oral corticosteroids reliance.

Statement of Educational Need

In the area of severe asthma, an emerging understanding of disease pathophysiology has identified therapeutic targets leading to better tolerated and more selective treatments. Biologics now fill a previously unmet need for effective treatment options for patients with eosinophilic-mediated respiratory disease. However, there are a number of eosinophil-mediated lung diseases associated with severe asthma that remain poorly understood, including eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES). Understanding the drivers of diseases associated with and sometimes concomitant to severe asthma is critical to effective management, as is the ability to identify which patients might benefit from available therapeutic agents.

Faculty

J. Mark FitzGerald, MB, MD, FRCPC (Faculty Presenter)
Professor of Respiratory Medicine
University of British Columbia
Vancouver, British Columbia

Disclosure:
Consulting Fees: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals, Inc, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi Regeneron, Teva Pharmaceutical Industries Ltd.

Fees for Non-CME/CE: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi Regeneron, Teva Pharmaceutical Industries Ltd.

Contracted Research/Funds paid directly to UBC: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Gossamer Bio, Novartis Pharmaceuticals Corporation, Sanofi Regeneron


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education (Integrity CE) and Global Education Group (Global) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity CE and Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following project managers/planners: Lindsay Borvansky, Ashley Cann, Donna Fausak, Andrea Funk, Amy Khalil, Liddy Knight, Ashley Marostica, RN, MSN, Patima Tanapat, PhD, reported that they or their spouses/life partners, have no financial relationships or relationships to products or devices with commercial interests related to the content of this CE activity.

Designation of Credit

Physician Credit
Integrity Continuing Education is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Integrity Continuing Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

Nursing Continuing Education
Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1.0 contact hour(s) is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Global Education Group designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number 0530-9999-20-069-H01-P)

This is a knowledge-based activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME/CE credit for this activity. During the period of June 25, 2020 through June 25, 2021, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. For pharmacist/ACPE learners, please check the CPE monitor for your CE credit within 60 days of the activity.

Statement of Commercial Support

This activity is supported by an educational grant from GlaxoSmithKline LLC.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education and GlaxoSmithKline do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education or GlaxoSmithKline. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Contact Information for Questions about the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or information@integrityce.com.

For information about the ANCC or ACPE accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: June 25, 2020
Expires: June 25, 2021
1 hour to complete

Accredited By

This CME activity for ACCME credit is provided by Integrity Continuing Education.
This CE activity for ANCC and ACPE credit is jointly provided by Global Education Group and Integrity Continuing Education.

Target Audience

This educational initiative has been designed for pulmonologists, allergists, fellows, medical residents, nurse practitioners, physician assistants, nurses, and other allied health care professionals who manage patients with asthma and other eosinophilic-associated diseases.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe the role of eosinophilia in severe asthma and EGPA
  • Explain why severe asthma comorbidities and rare orphan diseases have an impact on treatment of severe asthma
  • Differentiate between available biologic therapies and evaluate their impact on lung function, asthma exacerbations, and dependence on oral corticosteroids

Activity Description

This program was designed to increase the clinician’s understanding of severe eosinophilic diseases that target the lungs and enable them to differentiate between available treatments to facilitate improved symptoms, lighter disease burden, fewer exacerbations, and reduced oral corticosteroids reliance.

Statement of Educational Need

In the area of severe asthma, an emerging understanding of disease pathophysiology has identified therapeutic targets leading to better tolerated and more selective treatments. Biologics now fill a previously unmet need for effective treatment options for patients with eosinophilic-mediated respiratory disease. However, there are a number of eosinophil-mediated lung diseases associated with severe asthma that remain poorly understood, including eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES). Understanding the drivers of diseases associated with and sometimes concomitant to severe asthma is critical to effective management, as is the ability to identify which patients might benefit from available therapeutic agents.

Faculty

J. Mark FitzGerald, MB, MD, FRCPC (Faculty Presenter)
Professor of Respiratory Medicine
University of British Columbia
Vancouver, British Columbia

Disclosure:
Consulting Fees: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals, Inc, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi Regeneron, Teva Pharmaceutical Industries Ltd.

Fees for Non-CME/CE: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi Regeneron, Teva Pharmaceutical Industries Ltd.

Contracted Research/Funds paid directly to UBC: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Gossamer Bio, Novartis Pharmaceuticals Corporation, Sanofi Regeneron


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education (Integrity CE) and Global Education Group (Global) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity CE and Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following project managers/planners: Lindsay Borvansky, Ashley Cann, Donna Fausak, Andrea Funk, Amy Khalil, Liddy Knight, Ashley Marostica, RN, MSN, Patima Tanapat, PhD, reported that they or their spouses/life partners, have no financial relationships or relationships to products or devices with commercial interests related to the content of this CE activity.

Designation of Credit

Physician Credit
Integrity Continuing Education is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Integrity Continuing Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

Nursing Continuing Education
Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1.0 contact hour(s) is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Global Education Group designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number 0530-9999-20-069-H01-P)

This is a knowledge-based activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME/CE credit for this activity. During the period of June 25, 2020 through June 25, 2021, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. For pharmacist/ACPE learners, please check the CPE monitor for your CE credit within 60 days of the activity.

Statement of Commercial Support

This activity is supported by an educational grant from GlaxoSmithKline LLC.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education and GlaxoSmithKline do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education or GlaxoSmithKline. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Contact Information for Questions about the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or information@integrityce.com.

For information about the ANCC or ACPE accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Pages